6.
Pan S, Zhan Y, Chen X, Wu B, Liu B
. Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices. Front Oncol. 2019; 9:613.
PMC: 6620567.
DOI: 10.3389/fonc.2019.00613.
View
7.
Kim D, Langmead B, Salzberg S
. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015; 12(4):357-60.
PMC: 4655817.
DOI: 10.1038/nmeth.3317.
View
8.
Kreis N, Moon H, Wordeman L, Louwen F, Solbach C, Yuan J
. KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker. Crit Rev Clin Lab Sci. 2024; 61(6):404-434.
PMC: 11815995.
DOI: 10.1080/10408363.2024.2309933.
View
9.
Yin H, Que R, Liu C, Ji W, Sun B, Lin X
. Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma. Cancer Lett. 2018; 425:54-64.
DOI: 10.1016/j.canlet.2018.03.044.
View
10.
Song X, Du R, Gui H, Zhou M, Zhong W, Mao C
. Identification of potential hub genes related to the progression and prognosis of hepatocellular carcinoma through integrated bioinformatics analysis. Oncol Rep. 2019; 43(1):133-146.
PMC: 6908929.
DOI: 10.3892/or.2019.7400.
View
11.
Fu Z, Yang G, Wang T, Gao D, Lin D, Liu X
. Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma. J Environ Pathol Toxicol Oncol. 2023; 42(4):47-60.
DOI: 10.1615/JEnvironPatholToxicolOncol.2023045721.
View
12.
Unruhe B, Schroder E, Wunsch D, Knauer S
. An Old Flame Never Dies: Survivin in Cancer and Cellular Senescence. Gerontology. 2015; 62(2):173-81.
DOI: 10.1159/000432398.
View
13.
Reynolds L, Maallin S, Haston S, Martinez-Barbera J, Hodivala-Dilke K, Pedrosa A
. Effects of senescence on the tumour microenvironment and response to therapy. FEBS J. 2023; 291(11):2306-2319.
DOI: 10.1111/febs.16984.
View
14.
Du R, Li K, Zhou Z, Huang Y, Guo K, Zhang H
. Bioinformatics and experimental validation of an AURKA/TPX2 axis as a potential target in esophageal squamous cell carcinoma. Oncol Rep. 2023; 49(6).
PMC: 10170493.
DOI: 10.3892/or.2023.8553.
View
15.
Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G
. The hallmarks of aging. Cell. 2013; 153(6):1194-217.
PMC: 3836174.
DOI: 10.1016/j.cell.2013.05.039.
View
16.
Cui D, Wu Y, Wen D
. CD34, PCNA and CK19 expressions in AFP- hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018; 22(16):5200-5205.
DOI: 10.26355/eurrev_201808_15717.
View
17.
Sohn E, Flamme-Wiese M, Whitmore S, Wang K, Tucker B, Mullins R
. Loss of CD34 expression in aging human choriocapillaris endothelial cells. PLoS One. 2014; 9(1):e86538.
PMC: 3897719.
DOI: 10.1371/journal.pone.0086538.
View
18.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z
. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141.
PMC: 8454663.
DOI: 10.1016/j.xinn.2021.100141.
View
19.
Pezeshki S, Hashemi P, Salimi A, Ebrahimi S, Javanzad M, Monfaredan A
. Evaluation of and Expression in Prostate Cancer: Potential Biomarkers for Prostate Cancer Screening. Rep Biochem Mol Biol. 2021; 10(2):224-232.
PMC: 8480293.
DOI: 10.52547/rbmb.10.2.224.
View
20.
Yang X, Yang C, Zhang S, Geng H, Zhu A, Bernards R
. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024; 42(2):180-197.
DOI: 10.1016/j.ccell.2024.01.007.
View